Introduction {#section1-1533033818809694}
============

Baculoviral inhibitor of apoptosis (IAP) repeat (BIR)-containing protein 7, which is also called Livin, is a protein encoded by the *BIRC7* gene in human.^[@bibr1-1533033818809694]^ *BIRC7* encodes 2 splicing variants of Livin, termed Livin-α and Livin-β. Both proteins have a single copy of BIR and a Really Interesting New Gene (RING) -type zinc finger domain.^[@bibr2-1533033818809694]^ The BIR domain has a well-characterized role in interacting with caspases and inhibiting apoptosis, while the RING-type zinc finger domain has a putative E3 ubiquitin ligase activity and may enhance its antiapoptotic activity.^[@bibr1-1533033818809694],[@bibr3-1533033818809694]^

A series of previous studies showed that aberrant *BIRC7* expression is associated with tumorigenesis, development, and progression in a variety of human malignancies, such as melanoma,^[@bibr4-1533033818809694]^ non-small cell lung cancer,^[@bibr5-1533033818809694]^ malignant pleural mesothelioma,^[@bibr6-1533033818809694]^ gallbladder cancer,^[@bibr7-1533033818809694]^ breast cancer,^[@bibr8-1533033818809694]^ and prostate cancer.^[@bibr9-1533033818809694]^ In prostate cancer, upregulated Livin-α can promote cell proliferation by enhancing G1-S cell cycle transition^[@bibr9-1533033818809694]^ and enhance prostate cancer cell invasion via nuclear factor κB (NF-κB) signaling, and the downstream Fibronectin (FN) and C-X-C chemokine receptor type 4 (CXCR4) pathway.^[@bibr10-1533033818809694],[@bibr11-1533033818809694]^ Knockdown of endogenous Livin could significantly inhibit prostate cancer cell proliferation and enhance apoptosis.^[@bibr12-1533033818809694]^ Another recent study based on 43 paraffin-embedded prostate cancer tissues found that Livin expression was positively correlated to the pathological grading of prostate cancer.^[@bibr13-1533033818809694]^ These findings suggest that *BIRC7* also acts as an oncogene that modulates cancer cell proliferation and invasion and might be related to differentiation of prostate cancer.

Currently, radical prostatectomy remains a first-line therapeutic option for most patients with localized prostate cancer.^[@bibr14-1533033818809694]^ Biochemical recurrence (BCR), which is defined as detectable prostate-specific antigen (PSA) level after radical prostatectomy, or an increasing PSA level following radiation therapy, may signify local or metastatic recurrence.^[@bibr15-1533033818809694]^ Around 20% to 40% of the patients suffer BCR by 10 years after surgery.^[@bibr16-1533033818809694]^ In fact, the median overall survival (OS) of the patients after radical prostatectomy is usually over 15 years.^[@bibr17-1533033818809694]^ In comparison, the median OS was 14.7 years for men who had 1 BCR after surgery and further dropped to 13.6 years in patients who had 2 BCRs.^[@bibr14-1533033818809694]^ However, patients with BCR may have different clinical courses: some may suffer rapid disease progression and increased risk of prostate cancer-specific mortality, but some may have indolent course, which had little adverse influence on their survival.^[@bibr18-1533033818809694]^ Therefore, besides the use of PSA as an indicator, it is meaningful to explore other biomarkers for early prediction of recurrence.

In this study, we examined the association between *BIRC7* expression and the clinicopathological characteristics and the independent prognostic value of *BIRC7* in terms of recurrence-free survival (RFS).

Materials and Methods {#section2-1533033818809694}
=====================

Data Mining in The Cancer Genome Atlas {#section3-1533033818809694}
--------------------------------------

Data mining was performed in The Cancer Genome Atlas-prostate cancer (TCGA-PRAD), in which biopsy specimen of 497 prostate cancer tissues and 52 normal prostate tissues have *BIRC7* expression measured by RNAseq (IlluminaHiSeq). *BIRC7* expression data (log2 \[normalized count+1\]), gene-level thresholded GISTIC2-processed copy-number alteration (−2: homozygous deletion; −1: heterozygous loss, 0: copy-neutral; +1: low-level copy gain; +2: high-level amplification), DNA methylation (measured by Infinium Human Methylation 450K BeadChip) and relevant clinical data were downloaded by using the UCSC Xena browser (<https://xenabrowser.net/>).

Kaplan-Meier Curves of RFS {#section4-1533033818809694}
--------------------------

Kaplan-Meier curves of RFS after primary therapy were generated by GraphPad Prism v6.0. Receiver operating characteristic curves for recurrence was constructed and the optimal cutoff values of *BIRC7* expression were determined based on Youden index. Subgroup analysis was performed according to T stages and tumor grade.

Statistical Analysis {#section5-1533033818809694}
--------------------

Statistical analysis was performed using SPSS 19.0 and GraphPad Prism v6.0. Continuous variables were reported as means ± standard error of the mean. The group difference was compared by 2-tailed Student *t* test or analysis of vairance with Student-Newman-Keuls test as a post hoc test. The association between *BIRC7* expression and the clinicopathological parameters was assessed by using χ^2^ tests. The difference between the RFS curves was compared using the log-rank test. Univariate and multivariate Cox regression models were used to evaluate the independent prognostic values of *BIRC7* expression in terms of RFS. Pearson goodness of fit test was performed to assess the correlation between *BIRC7* expression and its DNA methylation. *P* \< .05 was considered statistically significant.

Results {#section6-1533033818809694}
=======

*BIRC7* Expression Is Upregulated in Prostate Cancer and Is Associated With Malignant Tumor Behaviors {#section7-1533033818809694}
-----------------------------------------------------------------------------------------------------

By using RNA-seq data in TCGA-PRAD, we found 497 prostate cancer tissues had *BIRC7* RNA expression measured. *BIRC7* expression was significantly higher in prostate cancer tissues than in normal prostate tissues (N = 52; [Figure 1A](#fig1-1533033818809694){ref-type="fig"}) and showed a trend of increase in advanced T stages ([Figure 1B](#fig1-1533033818809694){ref-type="fig"}). In addition, we also observed substantially higher *BIRC7* expression in nodal positive (N1) cases than in nodal negative (N0) cases ([Figure 1C](#fig1-1533033818809694){ref-type="fig"}) and in high-grade tumors (Gleason score 8-10) than in medium-grade tumors (Gleason score 6-7; [Figure 1D](#fig1-1533033818809694){ref-type="fig"}). Then, we compared the clinicopathological parameters in the patients with RFS data recorded (N = 436). The patients were divided into high and low *BIRC7* expression groups according to the optimal cutoff value ([Table 1](#table1-1533033818809694){ref-type="table"}). Results showed that the high *BIRC7* expression group had older ages (61.58 ± 0.42 vs 59.96 ± 0.54, *P* = .018), a higher proportion of nodal positive cases (47/235, 20.0% vs 15/135, 11.1%, *P* = .028), lower proportions of overall response rate (215/249, 86.3% vs 140/150, 93.3%, *P* = .031), R0 cases (163/254, 64.2% vs 118/155, 76.1%, *P* = .011) and medium-grade (Gleason score 6-7) tumors (144/273, 52.7% vs 118/163, 72.4%, *P* \< .0001), and a higher risk of recurrence (44/273, 16.1% vs 8/163, 4.9%, *P* = .0005; [Table 1](#table1-1533033818809694){ref-type="table"}). *PTEN* deletion has been considered as an important marker of RFS in prostate cancer.^[@bibr19-1533033818809694],[@bibr20-1533033818809694]^ In TCGA-PRAD, we also observed a high frequency of *PTEN* deletion (heterozygous loss and homozygous deletion/all tumor cases with copy number alteration data: 159/491) and associated decreased *PTEN* expression (Supplemental Figure 1A and B). However, no difference in *BIRC7* expression was observed in these groups (Supplemental Figure 1C). In addition, between the high and low *BIRC7* expression groups, we did not find any significant difference in *PTEN* copy number alterations ([Table 1](#table1-1533033818809694){ref-type="table"}). These results suggest that *BIRC7* expression is irrelevant to *PTEN* in prostate cancer.

![BIRC7 expression is upregulated in prostate cancer and is associated with malignant tumor behaviors. Comparison of *BIRC7* expression between prostate cancer tissues (N = 497) and normal prostate tissues (N = 52) (A), among T2/T3/T4 stage tumors (B), between nodal positive (N = 79) and negative (N = 345) tumors (C), and between high-grade (Gleason score 8-10; (N = 205) and medium-grade tumors (Gleason score 6-7; (N = 292).](10.1177_1533033818809694-fig1){#fig1-1533033818809694}

###### 

The Association Between *BIRC7* Expression and the Clinical Parameters in Patients With Prostate Cancer.

![](10.1177_1533033818809694-table1)

  Parameters                *BIRC7* Expression   χ^2^            *P* Value           
  ------------------------- -------------------- --------------- ----------- ------- --------
  Age (Mean ± SEM)          61.58 ± 0.42         59.96 ± 0.54                .018    
  PSA value (Mean ± SEM)    1.945 ± 1.354        0.685 ± 0.319               .37     
  T stages                  T2                   102             73          2.21    .14
  T3/T4                     166                  88                                  
  Null                      5                    2                                   
  N stages                  N0                   188             120         4.86    .028
  N1                        47                   15                                  
  Null                      38                   28                                  
  Primary therapy outcome   CR+PR                215             140         4.66    .031
  SD+PD                     34                   10                                  
  Discrepancy + null        24                   13                                  
  Radiation therapy         No                   222             141         3.36    .067
  Yes                       40                   14                                  
  Discrepancy + null        11                   8                                   
  Residual tumor            R0                   163             118         6.40    .011
  R1+R2                     91                   37                                  
  RX + null                 19                   8                                   
  Gleason score             6/7                  144             118         16.43   \<.001
  8/9/10                    129                  45                                  
  *PTEN* CNAs               Amplification        4               0           2.42    .30
  Copy neutral              179                  109                                 
  Deletion                  87                   53                                  
  Null                      3                    1                                   
  Recurrence                No                   229             155         12.21   \<.001
  Yes                       44                   8                                   

Abbreviations: CNAs, copy number alterations; CR, complete remission; PD, progressive disease; PR, partial remission; PSA, prostate-specific antigen; R0, No residual tumor; R1, Microscopic residual tumor; R2, Macroscopic residual tumor; RX, the presence of residual tumor cannot be assessed; SD, stable disease; SEM, standard error of the mean; null, no data.

*BIRC7* Upregulation Is Associated With Poor RFS in Prostate Cancer {#section8-1533033818809694}
-------------------------------------------------------------------

By generating Kaplan-Meier curves of RFS, we found that high *BIRC7* expression was associated with unfavorable RFS in prostate cancer (*P* = .0003; [Figure 2](#fig2-1533033818809694){ref-type="fig"}). To verify the robustness of the association, we performed subgroup analysis according to T stages and tumor grades. By using the Youden Index as the cutoff (\>1.285 vs ≤ 1.285), we found that *BIRC7* expression was not related to RFS in patients with T2 tumors (*P* = .080; [Figure 3A](#fig3-1533033818809694){ref-type="fig"}). However, high *BIRC7* expression (\> 0.92, N = 166) was significantly associated with poor RFS in T3/T4 tumors (*P* = .0007; [Figure 3B](#fig3-1533033818809694){ref-type="fig"}). To explore the independent prognostic value of *BIRC7* in these subgroups, we then conducted univariate and multivariate analysis with Cox regression model. Results showed that *BIRC7* expression was not an independent indicator of RFS in T2 tumors, but was independently associated with poor RFS in T3/T4 tumors (hazard ratio \[HR\]: 4.249, 95% confidence interval \[CI\]: 1.563-11.546, *P* = .005; [Table 2](#table2-1533033818809694){ref-type="table"}).

![Kaplan-Meier curves of RFS in prostate cancer. RFS indicates recurrence-free survival.](10.1177_1533033818809694-fig2){#fig2-1533033818809694}

![Kaplan-Meier curves of RFS in T2 (A) and T3/T4 (B) tumors. RFS indicates recurrence-free survival.](10.1177_1533033818809694-fig3){#fig3-1533033818809694}

###### 

Univariate and Multivariate Analysis of RFS in T2 and in T3/T4 Tumors.

![](10.1177_1533033818809694-table2)

  Parameters                                 Univariate Model   Multivariate Model                                           
  ------------------------------------------ ------------------ -------------------- ------- -------- ------ ------- ------- --------
  T2                                                                                                                         
   Age (continuous)                          .386               1.041                0.951   1.140                           
   N status: N0 vs N1                        .109               0.170                0.020   1.482                           
   Primary therapy outcome: SD/PD vs CR/PR   .006               10.114               1.949   52.486                          
   PSA value (continuous)                    .134               1.230                0.938   1.613                           
   Radiation therapy: No vs Yes                                                                                              
   Residual tumor: R1+R2 vs R0               .410               1.938                0.401   9.370                           
   Gleason score:8/9/10 vs 6/7               .039               4.002                1.070   14.975                          
  *BIRC7* expression: High vs low            .102               3.716                0.770   17.935                          
  T3/T4                                                                                                                      
   Age (continuous)                          .568               0.986                0.940   1.034                           
   N status: N0 vs N1                        .820               0.923                0.461   1.845                           
   Primary therapy outcome: SD/PD vs CR/PR   .011               2.276                1.203   4.308    .358   1.394   0.686   2.832
   PSA value (continuous)                    .027               1.043                1.005   1.082    .014   1.057   1.011   1.105
   Radiation therapy: No vs Yes              .339               0.695                0.330   1.464                           
   Residual tumor: R1+R2 vs R0               .012               2.214                1.187   4.129    .136   1.692   0.848   3.376
   Gleason score: 8/9/10 vs 6/7              \<.001             4.505                2.004   10.128   .027   2.634   1.118   6.205
  * BIRC7* expression: High vs Low           .002               3.999                1.685   9.490    .005   4.249   1.563   11.546

Abbreviations: CI, confidence interval; CR, complete remission; HR, hazard ratio; PD, progressive disease; PR, partial remission; PSA, prostate-specific antigen; RFS, recurrence-free survival.

In subgroup analysis according to the Gleason score, we found that high *BIRC7* expression (\>2.00, N = 67) was significantly associated with poor RFS in medium-grade tumors (Gleason score 6-7; *P* = .0003; [Figure 4A](#fig4-1533033818809694){ref-type="fig"}), but not in high-grade tumors (\> 0.90, N = 129; Gleason score 8-10; *P* = .10; [Figure 4B](#fig4-1533033818809694){ref-type="fig"}). Univariate and multivariate analysis showed that *BIRC7* expression was independently associated with unfavorable RFS in medium-grade tumors (HR: 6.041, 95% CI: 1.763-20.703, *P* = .004), but not in high-grade tumors ([Table 3](#table3-1533033818809694){ref-type="table"}).

![Kaplan-Meier curves of RFS in medium-grade (A) and high-grade (B) tumors. RFS indicates recurrence-free survival.](10.1177_1533033818809694-fig4){#fig4-1533033818809694}

###### 

Univariate and Multivariate Analysis of RFS in Medium-Grade and High-Grade Tumors.

![](10.1177_1533033818809694-table3)

  Parameters                                 Univariate Model   Multivariate Model                                           
  ------------------------------------------ ------------------ -------------------- ------- -------- ------ ------- ------- --------
  Gleason score 6/7                                                                                                          
   Age (continuous)                          .277               1.048                0.963   1.140                           
   T stages: T3/T4 vs T2                     .366               1.701                0.538   5.380                           
   N status: N0 vs N1                        .388               0.403                0.051   3.180                           
   Primary therapy outcome: D/PD vs CR/PR    .015               6.682                1.447   30.863   .110   3.595   0.749   17.264
   PSA value (continuous)                    .983               1.006                0.582   1.740                           
   Radiation therapy: No vs Yes              .390               0.404                0.051   3.181                           
   Residual tumor: R1+R2 vs R0               .273               1.959                0.589   6.522                           
  * BIRC7* expression: High vs Low           .002               6.716                2.015   22.381   .004   6.041   1.763   20.703
  Gleason score 8/9/10                                                                                                       
   Age (continuous)                          .399               0.980                0.936   1.027                           
   T stages: T3/T4 vs T2                     .184               2.020                0.715   5.707                           
   N status: N0 vs N1                        .508               1.271                0.626   2.581                           
   Primary therapy outcome: SD/PD vs CR/PR   .211               1.518                0.789   2.920                           
   PSA value (continuous)                    .085               1.034                0.995   1.073                           
   Radiation therapy: No vs Yes              .855               0.934                0.452   1.932                           
   Residual tumor: R1+R2 vs R0               .025               2.123                1.099   4.099                           
  * BIRC7* expression: High vs Low           .111               2.154                0.838   5.538                           

Abbreviations: CI, confidence interval; CR, complete remission; HR, hazard ratio; PD, progressive disease; PSA, prostate-specific antigen; RFS, recurrence-free survival; SD, stable disease.

*BIRC7* Dysregulation Is Related to Both Copy Number Alteration and Methylation {#section9-1533033818809694}
-------------------------------------------------------------------------------

To explore the mechanisms of *BIRC7* dysregulation in prostate cancer, we examined the correlation between its RNA expression and DNA copy number alteration/methylation by using deep-sequencing data in TCGA-PRAD ([Figure 5A](#fig5-1533033818809694){ref-type="fig"}). *BIRC7* copy number alteration was quantified in 492 out of 498 patients with primary prostate cancer. Forty patients (8.13%) had DNA amplification (+1/+2; [Figure 5A](#fig5-1533033818809694){ref-type="fig"}), which was associated with significantly upregulated *BIRC7* expression (*P* = .0033; [Figure 5B](#fig5-1533033818809694){ref-type="fig"}). The results of regression analysis showed a weak negative correlation between *BIRC7* expression and its DNA methylation (Pearson *r* = −0.23; [Figure 5C](#fig5-1533033818809694){ref-type="fig"}). These findings suggest that the expression of *BIRC7* in prostate cancer is at least regulated by both copy number alteration and DNA methylation.

![The association between *BIRC7* expression and its DNA copy number alteration/methylation. A, Heat map showing the correlation between *BIRC7* expression and its DNA copy number alteration/methylation; −2: homozygous deletion; −1: heterozygous Loss, 0: copy-neutral; +1: low-level copy gain; +2: high-level amplification. B, Comparison of *BIRC7* expression in groups with different *BIRC7* copy number alteration. C, Regression analysis of the correlation between *BIRC7* expression and its DNA methylation.](10.1177_1533033818809694-fig5){#fig5-1533033818809694}

Discussion {#section10-1533033818809694}
==========

In this study, we observed that *BIRC7* expression was significantly upregulated in prostate cancer tissues than in normal prostate tissues. In addition, by comparing the clinical parameters between high and low *BIRC7* expression groups, we observed that the high *BIRC7* expression group had lower ratios of overall response rate and medium-grade (Gleason score 6-7) tumors and higher proportions of nodal invasion and recurrence after surgery. Previous studies showed that Livin acts as a caspase inhibitor, which blocks caspase activation and further inhibits apoptosis.^[@bibr21-1533033818809694]^ In prostate cancer, upregulated Livin-α can facilitate S phase entry in prostate cancer cells and subsequently enhance their proliferation and survival.^[@bibr9-1533033818809694]^ It can also enhance prostate cancer cell invasion via NF-κB signaling, and the downstream FN and CXCR4 pathway.^[@bibr10-1533033818809694],[@bibr11-1533033818809694]^ These mechanisms help to explain the oncogenic properties of *BIRC7* in prostate cancer.

As an oncogene, the independent prognostic value of *BIRC7* was also observed in several cancers. In patients with rectal cancer, Livin expression was associated with unfavorable OS independent of TNM stage, local and distant recurrence, grade of differentiation, gender, and age.^[@bibr22-1533033818809694]^ In squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder, *BIRC7* expression was an independent poor prognostic factor in terms of postoperative survival.^[@bibr7-1533033818809694]^ Although the oncogenic effects of *BIRC7* have been reported in prostate cancer, its prognostic value has not been explored. In fact, current prognostic tools such as clinicopathological parameters lack sufficient accuracy to effectively predict recurrence in prostate cancer.^[@bibr23-1533033818809694]^ For example, PSA is one of the most important screening tools for prostate cancer. But its prognostic value is debated controversially due to limited specificity and imprecise prediction of tumor aggressiveness.^[@bibr24-1533033818809694]^ Therefore, it is necessary to explore other potential prognostic biomarkers for both early predictions and proactive use of adjuvant therapeutic options before frank recurrence. In this study, we further assessed the independent prognostic value of *BIRC7* in terms of RFS. Although Kaplan-Meier curves of RFS showed that high *BIRC7* expression was generally associated with poor RFS, the following subgroup analysis only confirmed the association in T3/T4 and in medium-grade tumors. Multivariate analysis showed that *BIRC7* expression was not an independent indicator of RFS in T2 or in high-grade tumors, even under the best cutoff model. In comparison, high *BIRC7* expression was independently associated with poor RFS in T3/T4 tumors (HR: 4.249, 95% CI: 1.563-11.546, *P* = .005) and in medium-grade tumors (HR: 6.041, 95% CI: 1.763-20.703, *P* = .004). These findings suggest that *BIRC7* expression might serve as a valuable biomarker of recurrence risk in advanced T stages and medium-grade prostate cancer. However, due to insufficiency data of OS in TCGA-PRAD, we failed to evaluate the prognostic value of *BIRC7* in terms of OS.

Previous studies suggest that Livin is a potential therapeutic target in some cancers.^[@bibr2-1533033818809694]^ Some therapeutic strategies for its inhibition, such as antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches have been tested in *in vitro* cell models and *in vivo* animal models and showed certain therapeutic values.^[@bibr2-1533033818809694],[@bibr25-1533033818809694]^ In this study, we found that high *BIRC7* expression was associated with poor therapeutic responses in prostate cancer. In addition, some previous studies found that Livin inhibition could also significantly inhibit prostate cancer cell proliferation and enhance apoptosis.^[@bibr9-1533033818809694],[@bibr12-1533033818809694]^ Therefore, it is meaningful to further explore the potential of Livin inhibition as a therapeutic option in prostate cancer in the future. Although we found that the expression of *BIRC7* in prostate cancer is at least regulated by both copy number alteration and DNA methylation, we could not exclude other genetic or epigenetic mechanisms influencing its transcription and translations. Thus, it is also necessary to investigate other potential mechanisms underlying its dysregulation in prostate cancer.

Conclusion {#section11-1533033818809694}
==========

*BIRC7* upregulation might serve as a valuable biomarker of increased recurrence risk in advanced T stages and medium-grade prostate cancer, which is at least regulated by both copy number alteration and DNA methylation.

Supplemental Material
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Click here for additional data file.
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